Enteropathy is a broad medical term for any disease or disorder of the intestines, though in practice it almost always refers to damage in the small bowel that disrupts its ability to absorb nutrients. The word shows up across dozens of conditions, from celiac disease to side effects of blood pressure medications to a widespread but underrecognized condition affecting children in low-income countries. What links them all is a gut lining that stops working properly, whether because the immune system attacks it, a drug erodes it, or chronic infection wears it down.
What All Enteropathies Share
The small intestine is lined with finger-like projections called villi that massively increase the surface area available to absorb food. In a healthy gut, these villi are tall and slender. In enteropathy, the defining change is villous atrophy: those projections flatten or blunt, sometimes disappearing entirely. When pathologists examine biopsied tissue, they typically see some combination of villous blunting, overgrowth of the crypts at the base of the villi, and an influx of immune cells into the lining itself.1PubMed Central. Non-Celiac Villous Atrophy-A Problem Still Underestimated These changes look strikingly similar regardless of the underlying cause, which is exactly why diagnosis can be so tricky.
Beneath that visible damage, the gut’s barrier function breaks down at a molecular level. The cells lining the intestine are sealed together by structures called tight junctions. In enteropathy, these seals loosen or redistribute, allowing molecules that should stay in the gut to leak into the bloodstream, and vice versa. Research on environmental enteropathy has shown that when multiple adjacent cells are shed from the villus surface, the tight junction proteins can no longer maintain the seal at all.2PLOS Neglected Tropical Diseases. Endomicroscopic and Transcriptomic Analysis of Impaired Barrier Function and Malabsorption in Environmental Enteropathy This barrier breakdown feeds a vicious cycle: the leaky gut triggers inflammation, and that inflammation further damages the tight junctions.3PubMed. Gastrointestinal Barrier Breakdown and Adipose Tissue Inflammation No FDA-approved therapies currently exist that directly restore tight junction integrity, which is part of why enteropathies remain so difficult to manage once established.4PubMed Central. Tight junctions: from molecules to gastrointestinal diseases
Celiac Disease, the Most Recognized Enteropathy
When most people hear “enteropathy,” celiac disease is the condition that comes to mind. It is an immune-mediated enteropathy triggered by gluten, the protein in wheat, barley, and rye, in people who carry certain genetic variants. The major genetic risk factor accounts for roughly 40% of the overall genetic susceptibility, but only a small fraction of people who carry those genes ever develop the disease.5PubMed Central. Immune development and intestinal microbiota in celiac disease Something in the environment or the gut microbiome appears to tip genetically susceptible people from tolerance into disease, and researchers are still working out exactly what that trigger is.
Diagnosis traditionally relies on biopsying the duodenum and grading the damage using a system known as the Marsh classification, which charts a spectrum from early immune-cell infiltration all the way to complete villous destruction.6PubMed Central. Diagnosing celiac disease: A critical overview Real-world follow-up of patients at the milder end of this spectrum shows why that grading matters: among patients with early Marsh lesions who stayed on a normal diet and had a repeat biopsy, a substantial proportion progressed to the most severe stage of villous atrophy, while those who switched to a gluten-free diet improved to normal tissue.7PubMed Central. Outcomes of Seropositive Patients with Marsh 1 Histology in Clinical Practice
A strict gluten-free diet remains the foundation of treatment, but a meaningful proportion of patients continue to have symptoms or abnormal biopsies despite their best efforts at avoiding gluten. Inadvertent gluten exposure is the most common culprit, and newer tests that measure gluten fragments in urine or stool can help identify hidden intake. For the rare subset with truly refractory disease, several experimental therapies are in early clinical trials, including drugs that neutralize gluten in the gut, block the inflammatory cascade, or attempt to retrain the immune system to tolerate gluten.8PubMed. Persistent symptoms and enteropathy in coeliac disease: clinical considerations and therapeutic opportunities
Environmental Enteric Dysfunction
Far less well known in wealthy countries but affecting millions worldwide, environmental enteric dysfunction (EED) is a subclinical enteropathy caused by constant fecal-oral contamination. The intestinal changes, villous blunting and chronic inflammation, were first described in biopsies from residents of tropical regions in the 1960s, though the clinical significance took decades to appreciate.9PubMed Central. Environmental Enteric Dysfunction in Children EED does not cause dramatic diarrhea in most cases. Instead, it quietly impairs nutrient absorption, blunts growth, and weakens the immune response to oral vaccines.
In its severe form, EED produces linear growth stunting, slowed brain development, and a poor response to oral vaccines, problems that have puzzled global health workers trying to improve child nutrition and immunization coverage in low-resource settings.10PubMed Central. Protection from environmental enteric dysfunction and growth improvement in malnourished newborns by amplification of secretory IgA The condition helps explain why nutritional supplements alone often fail to reverse stunting: you can deliver the nutrients, but a damaged gut cannot absorb them efficiently.
Diagnosing EED in the field is challenging because biopsy is invasive and impractical in the populations most affected. Researchers have turned to blood and stool biomarkers. In children in northeast Brazil, markers of gut barrier damage and immune activation, including antibodies against bacterial components and a protein released when intestinal cells are injured, correlated with worse growth outcomes.11PLOS ONE. Biomarkers of Environmental Enteropathy, Inflammation, Stunting, and Impaired Growth in Children in Northeast Brazil These biomarker panels are still being refined, but they represent a realistic path toward screening children at scale without requiring endoscopy.
Drug-Induced Enteropathies
Some of the most clinically important enteropathies are caused by medications. These can be particularly insidious because patients and doctors may not suspect their blood pressure pill or pain reliever is destroying the gut lining.
Olmesartan
Olmesartan, a widely prescribed angiotensin receptor blocker used for high blood pressure, can cause a severe enteropathy that closely mimics celiac disease in both symptoms and tissue appearance: villous atrophy, increased immune cells in the lining, diarrhea, weight loss, and nausea.12PubMed Central. Olmesartan-Induced Enteropathy In one referral-center series, most patients had been taking 40 mg per day for months or years before symptoms started, and the majority had been misdiagnosed with refractory celiac disease or unexplained malabsorption. Biopsies revealed total villous atrophy in most patients and a thick collagen band beneath the surface lining in about a third of them.13Mayo Clinic Proceedings. Severe Spruelike Enteropathy Associated With Olmesartan The good news is that stopping the drug leads to improvement. In reported cases, symptoms resolved once olmesartan was discontinued.14PubMed Central. Olmesartan and drug-induced enteropathy Other drugs in the same class do not appear to cause this problem at similar rates, making olmesartan something of an outlier.
NSAIDs
Nonsteroidal anti-inflammatory drugs, the class that includes ibuprofen and naproxen, are well known for causing stomach ulcers, but they also damage the small bowel. The mechanism involves more than just blocking the protective prostaglandins that keep the gut lining healthy. Bacterial invasion of the weakened mucosa plays a central role, and abnormal gut motility helps set the stage by moving bacteria to places they do not belong.15Digestion. NSAID-Induced Small Intestinal Damage – Roles of Various Pathogenic Factors Downstream, the body’s own inflammatory machinery amplifies the damage. Animal research has shown that a specific inflammatory complex becomes activated within hours of NSAID exposure, producing a cascade of signaling molecules that drive tissue injury. Mice engineered to lack key components of this pathway were substantially resistant to the damage.16PubMed. Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy In clinical practice, mesalazine (an anti-inflammatory drug used for inflammatory bowel disease) has shown some ability to heal mucosal injuries caused by naproxen.17PubMed Central. Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy
Immune Checkpoint Inhibitors and Immunosuppressants
A newer category of drug-induced enteropathy has emerged alongside cancer immunotherapy. Checkpoint inhibitors, drugs that unleash the immune system against tumors, can also turn that immune response against healthy intestinal tissue. Gastrointestinal side effects are among the most frequent and severe complications of these therapies.18Gut. Enterocolitis due to immune checkpoint inhibitors On the opposite end of the immune spectrum, immunosuppressants like mycophenolate, used after organ transplants, can also cause enteropathy. Research in mice has linked mycophenolate-induced gut damage to disruption of the gut microbiome and impaired production of short-chain fatty acids, the metabolic byproducts that help keep the intestinal lining healthy.19PubMed Central. Alteration of the gut microbiome in mycophenolate-induced enteropathy: impacts on the profile of short-chain fatty acids in a mouse model
Protein-Losing Enteropathy
Protein-losing enteropathy (PLE) is less a specific disease than a consequence that can arise from many different intestinal or cardiovascular conditions. In PLE, proteins leak out of the bloodstream and into the gut at rates faster than the body can replace them. The result is dangerously low levels of albumin and other blood proteins, leading to swelling, immune deficiency, and malnutrition.20PubMed Central. Clinical practice. Protein-losing enteropathy in children
The conditions that cause PLE fall broadly into two categories. In one, protein leaks from damaged intestinal lymphatic channels. When mucosal lymphatics rupture, they drain lymph fluid backward into the gut lumen, carrying proteins and a distinctive loss of CD4 immune cells that can help clinch the diagnosis.21PubMed Central. Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states In the other category, the mucosal surface itself erodes or becomes inflamed, and proteins simply leak through the gaps. Inflammatory bowel disease, infections, and certain cancers can all cause this pattern.
One of the more surprising settings for PLE is after cardiac surgery. The Fontan operation, performed in children born with a single functioning heart ventricle, reroutes blood flow in a way that raises pressure in the veins draining the gut. That elevated venous pressure can congest the intestinal lining and lymphatics badly enough to cause chronic protein loss.22PubMed. Protein-losing enteropathy and the Fontan operation Low cardiac output and abnormal lymphatic drainage both contribute to the problem.23PubMed. Protein-Losing Enteropathy Following Fontan Palliation PLE after Fontan surgery is a serious long-term complication and one that illustrates how enteropathy can originate from problems far removed from the gut itself.
Tropical Sprue and Other Infectious Causes
Tropical sprue is an enteropathy seen in people living in or returning from tropical regions. Unlike EED, which tends to be subclinical, tropical sprue causes overt malabsorption. The damaged enterocytes lose their ability to absorb carbohydrates, fats, fat-soluble vitamins, folic acid, and vitamin B12, leading to deficiency syndromes that can become severe. Biopsies show partial villous atrophy, deeper-than-normal crypts, and increased inflammatory cells in the tissue.24PubMed Central. Tropical Sprue: A Rare Cause of Malabsorption Syndrome The exact infectious agent has never been definitively identified, though bacterial overgrowth is considered central, and the condition typically responds to a prolonged course of antibiotics combined with folic acid replacement.
Rare Genetic Forms
At the far end of the rarity spectrum sit congenital enteropathies, conditions present from birth that result from mutations in genes critical for intestinal cell function. Microvillus inclusion disease, for example, arises from mutations affecting the molecular machinery that maintains the proper structure of the cell surface. The most classic genetic defect involves myosin Vb, a motor protein essential for cell polarity, though mutations in other genes have also been identified as causes.25PubMed Central. Microvillus Inclusion Disease: A Rare Mutation of STX3 in Exon 9 Causing Fatal Congenital Diarrheal Disease For most congenital diarrheal disorders, the disease gene is known, and genetic testing can provide a definitive diagnosis.26PubMed Central. Congenital diarrheal disorders: an updated diagnostic approach
IPEX syndrome (immune dysregulation, polyendocrinopathy, enteropathy, X-linked) is another rare genetic enteropathy, this one caused by mutations in a gene that controls regulatory immune cells. Without functioning regulatory cells, the immune system attacks the gut lining. Intractable diarrhea is a hallmark, driven by autoantibodies that target brush border proteins on the surface of intestinal cells.27PubMed. Autoantibodies to villin occur frequently in IPEX, a severe immune dysregulation, syndrome caused by mutation of FOXP3 These conditions are individually very rare but collectively important because they reveal fundamental mechanisms of how the gut maintains itself.
Radiation Enteropathy
Radiation therapy aimed at abdominal or pelvic tumors inevitably exposes nearby small bowel tissue to damage. The resulting radiation enteropathy can be acute, appearing during or shortly after treatment, or chronic, developing months to years later. Symptoms range from pain and bloating to diarrhea, urgency, and rectal bleeding, and the chronic form can significantly impair quality of life long after cancer treatment has ended.28PubMed Central. Radiation-induced small bowel disease: latest developments and clinical guidance Modern radiation techniques that minimize bowel exposure have reduced but not eliminated the problem. Chronic radiation enteropathy is especially frustrating because the tissue damage is permanent and progressive, driven by ongoing scarring and blood vessel changes rather than active inflammation.
When the Biopsy Looks Like Celiac but Isn’t
One of the trickiest diagnostic situations in gastroenterology is finding villous atrophy on a biopsy in someone whose celiac blood tests are negative. The list of conditions that can produce this picture, collectively called non-celiac villous atrophy, is long: drug reactions, infections, immune deficiencies, inflammatory conditions, and sometimes no identifiable cause at all.29PubMed. Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice The tissue changes can overlap so heavily that the biopsy alone cannot distinguish between causes.30PubMed Central. Seronegative Intestinal Villous Atrophy: A Diagnostic Challenge
This is where a thorough medication history becomes vital. As noted in the olmesartan cases above, patients were frequently misdiagnosed with refractory celiac disease before anyone thought to check their medication list. The European Society of Gastrointestinal Endoscopy has even weighed in on the limitations of various diagnostic tools, recommending against using capsule endoscopy as a first-line test for suspected celiac disease while acknowledging it can be useful in patients who cannot undergo standard endoscopy.31PubMed Central. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders When celiac testing is negative and a biopsy shows villous atrophy, the diagnostic workup fans out to consider drug effects, immune disorders, infections, and rarer causes.
The Microbiome Connection
Across virtually every form of enteropathy, gut bacteria play a role, whether as a trigger, an amplifier, or a casualty of the damage. Research into chronic intestinal inflammation in animal models has found that decreased levels of certain short-chain fatty acids, the metabolites produced when beneficial gut bacteria ferment dietary fiber, are associated with intestinal inflammation. Restoring healthy bacterial communities may suppress inflammation and improve immune function.32Journal of Veterinary Internal Medicine. Fecal short-chain fatty acid concentrations and dysbiosis in dogs with chronic enteropathy Much of this evidence comes from veterinary medicine, where chronic enteropathy in dogs is common and has become a productive research model. Elimination diets have strong evidence supporting their use as first-line treatment in dogs and cats with chronic enteropathy, with some animals achieving long-term remission on dietary management alone.33Journal of Veterinary Internal Medicine. Narrative review of therapies for chronic enteropathies in dogs and cats
Whether findings from veterinary enteropathy models translate directly to humans is an open question, but the overlap is striking. In both species, chronic gut inflammation disrupts microbial communities, reduces protective metabolites, and damages the absorptive surface. Manipulating the microbiome through diet, probiotics, or fecal transplant is an active area of investigation in human enteropathies as well, though high-quality clinical trial data in people remain sparse for most forms beyond celiac disease.